AAK1 (AP2-associated kinase 1) is a serine/threonine kinase that regulates clathrin-mediated endocytosis through phosphorylation of the AP-2 adaptor complex, particularly the μ2 subunit 1. This endocytic function is critical for multiple cellular processes and disease pathways. In viral infections, AAK1 plays a central role in the entry and lifecycle of multiple viruses including hepatitis C, Dengue, Ebola, COVID-19, and Toscana virus 12, making it a validated antiviral target. Additionally, AAK1 regulates transferrin receptor 1 (TFR1) endocytosis through a PKCβII-AAK1-AP2M1 pathway, controlling iron uptake and ferroptotic cell death in breast cancer 3. Clinically, AAK1 inhibition has emerged as a promising therapeutic strategy. AAK1 inhibitors are in advanced clinical development for neuropathic pain treatment, demonstrating efficacy in rodent pain models with brain target occupancy correlating to analgesic effects 45. Recent chemical proteomics identified novel selective AAK1 inhibitors like TIM-098a with improved potency 6. Beyond pain, AAK1 represents a druggable target for neuropsychiatric disorders (schizophrenia, Parkinson's disease, Alzheimer's disease) and potentially amyotrophic lateral sclerosis 78.